Overview

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

Status:
Recruiting

Trial end date:
2023-05-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate adverse events and tolerability of single and multiple doses of ABBV-903, and to assess how the drug moves through the body in healthy adult volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Itraconazole